Arsenicals and inhibitors of histone deacetylase as anticancer therapy.
Warrell
R P
RP
Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Centre, New York, NY 10021, USA. rwarrell@mskcc.org
D000107:Acetylation / Q000187:drug effects; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002648:Child; D002681:China; D002843:Chromatin / Q000378:metabolism; D004341:Drug Evaluation; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy; D007964:Leukocytosis / Q000139:chemically induced; D008549:Melarsoprol / Q000009:adverse effects / Q000627:therapeutic use; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000188:drug therapy*; D009422:Nervous System Diseases / Q000139:chemically induced; D010087:Oxides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D010654:Phenylbutyrates / Q000627:therapeutic use*; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D016879:Salvage Therapy; D014212:Tretinoin / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001152:Arsenicals; D002843:Chromatin; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D009363:Neoplasm Proteins; D010087:Oxides; D010654:Phenylbutyrates; D014212:Tretinoin; C075773:4-phenylbutyric acid; D000077237:Arsenic Trioxide; D008549:Melarsoprol